Dernières nouvelles pour Ayr Wellness (OTC:AYRWF) Stock

Ayr Wellness Inc is a vertically integrated cannabis multi-state operator in the United States of America. Through its subsidiaries in various U.S. states, it is involved in the cultivation, manufacturing, and retail of cannabis products and branded cannabis packaged goods. It operates in one operating segment, cannabis sales. It has a single operating and reportable segment, the production and sale of cannabis.

Ordinary Shares (Sub, Restricted, Ltd Voting)

Ayr Wellness Inc

Goldman Sachs analyst Noah Poponak maintains Mercury Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRCY#NASDAQ">MRCY</a>) with a Sell and raises the price target from $30 to $33.

News

Price Target

Analyst Ratings

MRCY

Goldman Sachs Maintains Sell on Mercury Sys, Raises Price Target to $33

WIIM

BLMN

BROS

CAVA

CBRL

DNUT

SBUX

SHAK

TXRH

WING

YUMC

Shares of restaurant companies are trading higher after the US and China agreed to a temporary reduction in most tariffs on each other's goods. This could alleviate supply chain uncertainty in the sector.

Wall Street analysts rerated Coinbase Global, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) on Friday after the company reported disappointing <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45302422/coinbase-q1-earnings-highlights-revenue-eps-miss-2025" rel="noreferrer noopener">first-quarter results</a> on Thursday.
Rosenblatt analyst Chris Brendler maintained Coinbase Global with a Buy and a <a href="https://www.benzinga.com/quote/COIN/analyst-ratings" target="_blank" rel="noreferrer noopener">$260 price target</a>.
Needham analyst John Todaro reiterated Coinbase Global with a Buy and lowered the price target from $330 to $270.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45155666/robinhood-stock-falls-after-analysts-cite-weak-crypto-volumes-and-market-headwinds-in-q2-outlook" rel="noreferrer noopener">Robinhood Stock Falls After Analysts Cite Weak Crypto Volumes And Market Headwinds In Q2 Outlook</a>
Rosenblatt: Revenue of $2.03 billion missed consensus of $2.10 billion by ~3% but came in slightly higher than Brendler&#8217;s estimate. 
Despite multiple attempts to anticipate trading weakness, transaction revenue still missed the analyst&#8217;s below consensus estimate ($1.26 billion versus his $1.30 billion) as high-yielding Consumer volumes were in line, but take rates declined more than expected in both Consumer and Institutional. 
On a positive note, MTUs of 9.7 million exceeded expectations (consensus 9.2 million), showing strength in platform engagement even as spot trading volumes declined sequentially.
In Brendler&#8217;s recent initiation, expanding opportunities outside the core trading business represented a key component of his thesis, as these largely recurring revenue streams should boost the multiple. This quarter, the analyst saw trading weakness more than offset by strength in Subscription and Services Revenue as Stablecoins were even better than anticipated and Other beat due to growth in premium offerings (Prime). 
The biggest positive surprise versus Brendler&#8217;s estimates was in Blockchain revenue, as despite a 35+ % decline in token prices, staking revenue only fell 8.5% sequentially versus the analyst&#8217;s -20% estimate.
Coinbase Global&#8217;s acquisition of Deribit is expected to close by year-end and should be immediately accretive to adjusted EBITDA. The deal is perfectly timed as it cements Coinbase Global&#8217;s leadership in the high-growth derivatives market and turbocharges its international exchange. Even better, Deribit&#8217;s $1 trillion+ in trading volumes are all outside the U.S., and with domestic regulatory clarity coming soon, Brendler noted the synergies could be substantial. Combined with a lower-than-expected price tag of $2.9 billion, this is one of the most compelling acquisitions the analyst noted in a long time.
Brendler projected second-quarter revenue of $1.78 billion and adjusted EPS of $2.48.
Needham: Coinbase Global reported a narrow top-line Street miss but modestly beat analyst Todaro&#8217;s estimates. The take rate modestly declined in the crypto transaction segment for both retail and institutional customers. Positive call-outs in the quarter were around USDC and the recently announced Deribit acquisition, which is expected to close by year-end 2025.
The $2.9 billion deal consists of $700 million in cash and 11 million shares of Coinbase Global stock.
The analyst noted the offering, which will be primarily geared for international markets, allows Coinbase Global to become a major player in derivatives and internationally. Additionally, Coinbase Global&#8217;s international exchange launched 39 new perpetual contracts and expanded the asset collateral type to 8 assets from 3.
Coinbase Global&#8217;s volume mix has recently been more Bitcoin and Ethereum than alt-coins, suggesting a greater shift towards institutional volume than retail for the second quarter. This negatively affects revenues as Coinbase Global has a significantly higher take rate on retail than institutional.
Additionally, April and May volumes are trending notably lower than average monthly volumes for the first quarter.
The good news is crypto asset prices recently inflected with Bitcoin rising back over $100k and a strong performance among alt-coins.
Historically, crypto asset prices find a bottom before volumes do, which suggests that with prices already inflecting, volumes should start seeing a bottom in the next one to two months. Nonetheless, Todaro lowered his fiscal 2025 and 2026 estimates to reflect lower volume estimates than his prior forecast.
Todaro projected second-quarter revenue of $1.56 billion and EPS of 80 cents.
COIN Price Action: Coinbase stock is up 5.74% to $210.76 at publication on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44672428/analyst-warns-tariffs-could-push-us-bitcoin-mining-build-costs-20-higher" target="_blank" rel="noreferrer noopener">Analyst Warns Tariffs Could Push US Bitcoin Mining Build Costs 20% Higher</a></li>
</ul>
Photo: Shuttestock

Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Reiteration

Trading Ideas

COIN

Coinbase's Subscription Gains, Deribit Acquisition, Blockchain Revenue Strength Prompt Analyst Support

Goldman Sachs analyst Andrea Tan maintains Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) with a Buy and lowers the price target from $16 to $8.

IOVA

Goldman Sachs Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $8

COTY

ULTA

Shares of beauty and cosmetic companies are trading higher after the US and China agreed to a temporary reduction in most tariffs on each other's goods. This could alleviate supply chain uncertainty in the sector.

Goldman Sachs analyst Eric Sheridan maintains Groupon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) with a Sell and raises the price target from $9 to $15.

GRPN

Goldman Sachs Maintains Sell on Groupon, Raises Price Target to $15

Wells Fargo analyst Marc Torrente maintains Post Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POST#NYSE">POST</a>) with a Equal-Weight and lowers the price target from $124 to $120.

POST

Wells Fargo Maintains Equal-Weight on Post Holdings, Lowers Price Target to $120

<h3>Gainers</h3>
<ul>
<li>Top Win International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOPW#NASDAQ">TOPW</a>) stock rose 44.5% to $5.55 during Monday's regular session. The company's market cap stands at $137.9 million. </li>
<li>Funko (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>) stock rose 41.02% to $4.95. The company's market cap stands at $266.7 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>Hamilton Beach Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBB#NYSE">HBB</a>) stock moved upwards by 27.36% to $18.48. The company's market cap stands at $249.7 million. </li>
<li>Ruanyun Edai Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYET#NASDAQ">RYET</a>) stock rose 25.72% to $11.9. The company's market cap stands at $401.6 million. </li>
<li>Allied Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGAE#NASDAQ">AGAE</a>) stock increased by 25.22% to $1.74. The market value of their outstanding shares is at $76.7 million. </li>
<li>WeRide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>) shares rose 24.71% to $9.99. The company's market cap stands at $2.7 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Superior Industries Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUP#NYSE">SUP</a>) shares decreased by 68.4% to $0.91 during Monday's regular session. The company's market cap stands at $26.2 million. The company's, Q1 earnings came out today. </li>
<li>Netclass Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTCL#NASDAQ">NTCL</a>) stock fell 27.92% to $20.4. The market value of their outstanding shares is at $363.7 million. </li>
<li>Classover Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDZ#NASDAQ">KIDZ</a>) shares fell 18.94% to $3.75. The market value of their outstanding shares is at $83.3 million. </li>
<li>Zapp Electric Vehicles Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>) stock declined by 17.59% to $0.33. The market value of their outstanding shares is at $2.5 million. </li>
<li>Twin Vee PowerCats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEE#NASDAQ">VEEE</a>) stock decreased by 14.25% to $2.95. The market value of their outstanding shares is at $4.3 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>Mullen Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) shares decreased by 14.13% to $0.17. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AGAE

FNKO

KIDZ

MULN

NTCL

RYET

TOPW

VEEE

ZAPP

12 Consumer Discretionary Stocks Moving In Monday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) shares increased by 296.0% to $15.45 during Monday's regular session. The company's market cap stands at $92.3 million. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) stock rose 93.34% to $1.79. The market value of their outstanding shares is at $143.7 million. As per the press release, Q1 earnings came out today. </li>
<li>Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) shares increased by 29.55% to $3.77. The market value of their outstanding shares is at $95.4 million. The company's, Q1 earnings came out today. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock moved upwards by 25.98% to $461.12. The market value of their outstanding shares is at $6.0 billion. </li>
<li>Aligos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGS#NASDAQ">ALGS</a>) stock increased by 22.76% to $5.5. The market value of their outstanding shares is at $33.6 million. The company's, Q1 earnings came out 4 days ago. </li>
<li>Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) shares rose 22.75% to $0.79. The market value of their outstanding shares is at $95.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) shares declined by 28.8% to $4.4 during Monday's regular session. The company's market cap stands at $254.9 million. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) shares declined by 20.0% to $0.12. The company's market cap stands at $2.9 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares fell 15.02% to $0.52. The company's market cap stands at $1.1 million. </li>
<li>Apimeds Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/APUS#AMEX">APUS</a>) shares fell 13.19% to $1.91. The company's market cap stands at $24.2 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) stock fell 11.18% to $0.14. The company's market cap stands at $4.0 million. </li>
<li>Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) shares declined by 10.69% to $2.92. The market value of their outstanding shares is at $15.6 million. As per the news, the Q1 earnings report came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AGEN

ALGS

APUS

AXDX

CTMX

IVVD

KDLY

LPCN

OMER

WORX

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Monday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>WANG &amp; LEE Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) shares rose 71.9% to $0.3 during Monday's regular session. The company's market cap stands at $6.3 million. </li>
<li>Lichen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) shares increased by 56.49% to $5.18. The market value of their outstanding shares is at $3.1 million. </li>
<li>Jayud Global Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYD#NASDAQ">JYD</a>) stock increased by 42.42% to $0.31. The company's market cap stands at $29.1 million. </li>
<li>Ming Shing Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSW#NASDAQ">MSW</a>) stock moved upwards by 30.95% to $4.95. The company's market cap stands at $64.2 million. </li>
<li>Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) stock increased by 28.71% to $5.89. The company's market cap stands at $766.6 million. As per the news, the Q2 earnings report came out 3 days ago. </li>
<li>Marwynn Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MWYN#NASDAQ">MWYN</a>) shares rose 26.28% to $7.27. The market value of their outstanding shares is at $124.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Nuvve Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) shares fell 47.1% to $1.47 during Monday's regular session. The market value of their outstanding shares is at $4.5 million. </li>
<li>Intelligent Living (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILAG#NASDAQ">ILAG</a>) shares decreased by 11.71% to $0.45. The market value of their outstanding shares is at $8.0 million. </li>
<li>FGI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGI#NASDAQ">FGI</a>) stock declined by 10.65% to $0.69. The company's market cap stands at $6.5 million. </li>
<li>Decent Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXST#NASDAQ">DXST</a>) stock fell 9.77% to $1.31. The company's market cap stands at $21.2 million. </li>
<li>JE Cleantech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JCSE#NASDAQ">JCSE</a>) shares decreased by 9.66% to $1.22. The market value of their outstanding shares is at $6.4 million. </li>
<li>Centuri Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRI#NYSE">CTRI</a>) stock declined by 9.61% to $19.29. The company's market cap stands at $1.7 billion. As per the press release, Q1 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTRI

DXST

FLNC

ILAG

JCSE

LICN

MWYN

NVVE

WLGS

12 Industrials Stocks Moving In Monday's Intraday Session

MTSR

Metsera shares are trading higher after the company reported a Q1 EPS beat.

<h3>Gainers</h3>
<ul>
<li>Gryphon Digital Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) stock increased by 238.5% to $1.76 during Monday's regular session. The company's market cap stands at $122.0 million. </li>
<li>Taoping (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TAOP#NASDAQ">TAOP</a>) shares increased by 143.98% to $0.4. The company's market cap stands at $5.3 million. </li>
<li>CISO Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CISO#NASDAQ">CISO</a>) stock rose 31.18% to $1.32. The company's market cap stands at $19.1 million. </li>
<li>Telos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>) shares increased by 30.6% to $2.56. The company's market cap stands at $191.6 million. The company's, Q1 earnings came out yesterday. </li>
<li>MicroAlgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) shares increased by 30.55% to $3.06. The company's market cap stands at $30.4 million. </li>
<li>VNET Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>) shares increased by 22.23% to $7.29. The market value of their outstanding shares is at $1.9 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Abits Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABTS#NASDAQ">ABTS</a>) shares decreased by 58.4% to $3.5 during Monday's regular session. The market value of their outstanding shares is at $8.2 million. </li>
<li>BTCS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCS#NASDAQ">BTCS</a>) stock declined by 34.09% to $2.05. The company's market cap stands at $41.1 million. </li>
<li>Digital Ally (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>) stock fell 14.76% to $0.04. </li>
<li>Marin Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) shares declined by 13.65% to $1.2. The company's market cap stands at $3.7 million. </li>
<li>Saiheat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIH#NASDAQ">SAIH</a>) stock decreased by 13.52% to $6.24. The company's market cap stands at $10.5 million. </li>
<li>Brand Engagement Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) stock declined by 13.13% to $0.28. The company's market cap stands at $11.4 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABTS

BNAI

BTCS

CISO

DGLY

GRYP

MLGO

MRIN

SAIH

TAOP

VNET

12 Information Technology Stocks Moving In Monday's Intraday Session

Goldman Sachs analyst Eric Sheridan maintains Grindr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRND#NYSE">GRND</a>) with a Buy and raises the price target from $20 to $26.

GRND

Goldman Sachs Maintains Buy on Grindr, Raises Price Target to $26

Macerich shares are trading higher after the company reported Q1 financial results and beat its FFO and sales estimates.

Wells Fargo analyst Richard Garchitorena maintains Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) with a Overweight and raises the price target from $73 to $79.

CTVA

Wells Fargo Maintains Overweight on Corteva, Raises Price Target to $79

Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-13. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Acurx Pharmaceuticals to report an earnings per share (EPS) of $-0.14.
The announcement from Acurx Pharmaceuticals is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS beat by $0.01, leading to a 3.13% increase in the share price on the subsequent day.
Here's a look at Acurx Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.18</td>
<td>-0.20</td>
<td>-0.22</td>
<td>-0.24</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.17</td>
<td>-0.17</td>
<td>-0.26</td>
<td>-0.28</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
<td>8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747069525_0.png" alt="eps graph" />
<h3>Acurx Pharmaceuticals Share Price Analysis</h3>
Shares of Acurx Pharmaceuticals were trading at $0.36 as of May 09. Over the last 52-week period, shares are down 81.2%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/ACXP/earnings">To track all earnings releases for Acurx Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

ACXP

A Look Ahead: Acurx Pharmaceuticals's Earnings Forecast

Goldman Sachs analyst Noah Poponak maintains Embraer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERJ#NYSE">ERJ</a>) with a Buy and raises the price target from $54 to $60.

Embraer-Empresa Brasileira De Aeronautica

Goldman Sachs Maintains Buy on Embraer, Raises Price Target to $60

Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-13. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Tenon Medical will report an earnings per share (EPS) of $-1.06.
Tenon Medical bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $2.79, leading to a 9.91% drop in the share price on the subsequent day.

<img src="https://www.benzinga.com/files/images/story/2025/1747069509_0.png" alt="eps graph" />
<h3>Performance of Tenon Medical Shares</h3>
Shares of Tenon Medical were trading at $1.13 as of May 09. Over the last 52-week period, shares are down 83.67%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Analyst Opinions on Tenon Medical</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Tenon Medical.
The consensus rating for Tenon Medical is Buy, derived from 1 analyst ratings. An average one-year price target of $3.0 implies a potential 165.49% upside.
<h3>Peer Ratings Overview</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of SINTX Technologies, Strata Skin Sciences and Ekso Bionics Holdings, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for SINTX Technologies, with an average 1-year price target of $30.0, suggesting a potential 2554.87% upside.</li>
<li>Analysts currently favor an Buy trajectory for Strata Skin Sciences, with an average 1-year price target of $6.0, suggesting a potential 430.97% upside.</li>
<li>Analysts currently favor an Buy trajectory for Ekso Bionics Holdings, with an average 1-year price target of $4.67, suggesting a potential 313.27% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
The peer analysis summary offers a detailed examination of key metrics for SINTX Technologies, Strata Skin Sciences and Ekso Bionics Holdings, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tenon Medical</td>
<td>Buy</td>
<td>-4.70%</td>
<td>$353K</td>
<td>-92.73%</td>
</tr>
<tr>
<td>SINTX Technologies</td>
<td>Buy</td>
<td>-67.07%</td>
<td>$38K</td>
<td>-35.78%</td>
</tr>
<tr>
<td>Strata Skin Sciences</td>
<td>Buy</td>
<td>10.21%</td>
<td>$5.76M</td>
<td>-62.83%</td>
</tr>
<tr>
<td>Ekso Bionics Holdings</td>
<td>Buy</td>
<td>5.01%</td>
<td>$2.71M</td>
<td>-24.75%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Tenon Medical ranks at the bottom for Revenue Growth and Gross Profit, indicating negative growth and lower profit margins compared to peers. However, it ranks at the top for Return on Equity, suggesting better performance in generating profits relative to shareholders' equity. Overall, Tenon Medical's financial performance is mixed compared to its peers.
<h3>Discovering Tenon Medical: A Closer Look</h3>
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
<h3>Tenon Medical: Financial Performance Dissected</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Negative Revenue Trend: Examining Tenon Medical's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -4.7% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Tenon Medical's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -400.91% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Tenon Medical's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -92.73%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Tenon Medical's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -26.98% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.19.
<a href="https://www.benzinga.com/quote/TNON/earnings">To track all earnings releases for Tenon Medical visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TNON

A Look Ahead: Tenon Medical's Earnings Forecast

Wells Fargo analyst Finian O'Shea maintains Barings BDC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBDC#NYSE">BBDC</a>) with a Equal-Weight and lowers the price target from $9 to $8.5.

BBDC

Wells Fargo Maintains Equal-Weight on Barings BDC, Lowers Price Target to $8.5

Goldman Sachs analyst Kash Rangan maintains Definitive Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DH#NASDAQ">DH</a>) with a Neutral and raises the price target from $3 to $3.4.

Goldman Sachs Maintains Neutral on Definitive Healthcare, Raises Price Target to $3.4

Press Releases

General

AYR Launches Later Days Fruit-Flavored Vape Collection

AYR's Flagship Product Brand, kynd, Celebrates 10-Year Anniversary with National Charitable Campaign

AYR Wellness Appoints George Denardo as President

Management

AYR Wellness Announces Leadership Update

AYR Wellness to Hold Fourth Quarter and Full Year 2024 Conference Call on March 6 at 8:30 a.m. ET

Comments

Ayr Wellness

Actualités

Dernières nouvelles pour Ayr Wellness (OTC:AYRWF) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL